The use of unfractionated heparin, the traditional antithrombotic agent during percutaneous coronary interventions (PCI), is associated with the risk of heparin-induced thrombocytopenia, a rare but often fatal clinical condition. This article focuses on several issues related to heparin-induced immune-mediated thrombocytopenia (HIT, type II) and alternative modes of periprocedural anticoagulation in patients with suspected or known HIT.
The hypercoagulable state characterizing HIT, along with mechanical plaque disruption resulting from PCI place patients with HIT at particular risk of thrombosis during PCI. Given that a diagnosis of HIT precludes any further use of heparin, other treatment modalities are essential. Direct thrombin inhibitors are the drugs of choice in this challenging situation. These agents offer several advantages as anticoagulants for patients with HIT: (1) the ability to inhibit both thrombin that is bound to fibrin (clot-bound thrombin) and fluid-phase free thrombin; (2) rapid achievement of steady state; and (3) no cross-reactivity with HIT antibodies. Recent data on the use of bivalirudin, lepirudin, and argatroban in the setting of PCI in patients with HIT are encouraging. Optimal dosing regimens for argatroban, lepirudin, and bivalirudin should be further established in PCI patients.
KEYWORDS
Heparin - thrombocytopenia - direct thrombin inhibitors - heparin-induced thrombocytopenia - HIT
REFERENCES
-
1
Brieger D B, Mak K H, Kottke-Marchant K, Topol E J.
Heparin-induced thrombocytopenia.
J Am Coll Cardiol.
1998;
31
1449-1459
-
2
Warkentin T E.
Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia.
Arch Pathol Lab Med.
2002;
126
1415-1423
-
3
Bell W R, Royall R M.
Heparin-associated thrombocytopenia: a comparison of three heparin preparations.
N Engl J Med.
1980;
303
902-907
-
4
Warkentin T E, Levine M N, Hirsh J et al..
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.
N Engl J Med.
1995;
332
1330-1335
-
5
Brushwood D B.
Hospital liable for allergic reaction to heparin used in injection flush.
Am J Hosp Pharm.
1992;
49
1491-1492
-
6
Heeger P S, Backstrom J T.
Heparin flushes and thrombocytopenia.
Ann Intern Med.
1986;
105
143
-
7
Laster J, Silver D.
Heparin-coated catheters and heparin-induced thrombocytopenia.
J Vasc Surg.
1988;
7
667-672
-
8
Cruz D, Karlsberg R, Takano Y, Vora D, Tobis J.
Subacute stent thrombosis associated with a heparin-coated stent and heparin-induced thrombocytopenia.
Catheter Cardiovasc Interv.
2003;
58
80-83
-
9 Lee D P, Warkentin T E. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. 2nd ed. New York; Marcel Dekker 2001: 87-121
-
10
Warkentin T E, Sheppard J A, Horsewood P, Simpson P J, Moore J C, Kelton J G.
Impact of the patient population on the risk for heparin-induced thrombocytopenia.
Blood.
2000;
96
1703-1708
-
11
Hirsh J, Warkentin T E, Shaughnessy S G et al..
Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety?.
Chest.
2001;
119 (1 suppl)
64-94
-
12
Warkentin T E, Kelton J G.
Temporal aspects of heparin-induced thrombocytopenia.
N Engl J Med.
2001;
344
1286-1292
-
13
Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson L E, Greinacher A.
Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or re-exposure to heparin.
Chest.
2002;
122
37-42
-
14
Warkentin T E, Kelton J G.
Delayed-onset heparin-induced thrombocytopenia and thrombosis.
Ann Intern Med.
2001;
135
502-506
-
15 Alban S, Greinacher A. Role of sulfated polysaccharides in the pathogenesis of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. 2nd ed. New York; Marcel Dekker 2001: 167-187
-
16 Admiral J, Meter D. Heparin-dependent antigens in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. 2nd ed. New York; Marcel Dekker 2001: 137-148
-
17
Boshkov L K, Warkentin T E, Hayward C P, Andrew M, Kelton J G.
Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies.
Br J Haematol.
1993;
84
322-328
-
18
Cines D B, Tomaski A, Tannenbaum S.
Immune endothelial-cell injury in heparin-associated thrombocytopenia.
N Engl J Med.
1987;
316
581-589
-
19
Warkentin T E, Hayward C P, Boshkov L K et al..
Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia.
Blood.
1994;
84
3691-3699
-
20
Warkentin T E.
Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia.
Transfus Med Rev.
1996;
10
249-258
-
21
Burgess J K, Lindeman R, Chesterman C N, Chong B H.
Single amino acid mutation of Fc gamma receptor is associated with the development of heparin-induced thrombocytopenia.
Br J Haematol.
1995;
91
761-766
-
22 Warkentin T E. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. 2nd ed. New York; Marcel Dekker 2001: 43-86
-
23
Singer R L, Mannion J D, Bauer T L, Armenti F R, Edie R N.
Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass.
Chest.
1993;
104
1436-1440
-
24
Guittard M, Pradalier A, Vincent D, Dry J.
Right intraventricular thrombosis and thrombopenia due to heparin.
Presse Med.
1988;
17
871
-
25
Arthur C K, Grant S J, Murray W K, Isbister J P, Stiel J N, Lauer C S.
Heparin-associated acute adrenal insufficiency.
Aust N Z J Med.
1985;
15
454-455
-
26
Laster J, Cikrit D, Walker N, Silver D.
The heparin-induced thrombocytopenia syndrome: an update.
Surgery.
1987;
102
763-770
-
27
Cimo P L, Moake J L, Weinger R S, Ben-Menachem Y B, Khalil K G.
Heparin-induced thrombocytopenia: association with a platelet aggregating factor and arterial thromboses.
Am J Hematol.
1979;
6
125-133
-
28
Warkentin T E.
Heparin-induced skin lesions.
Br J Haematol.
1996;
92
494-497
-
29
King D J, Kelton J G.
Heparin-associated thrombocytopenia.
Ann Intern Med.
1984;
100
535-540
-
30
Matthai Jr W H.
Use of argatroban during percutaneous coronary interventions in patients with heparin-induced thrombocytopenia.
Semin Thromb Hemost.
1999;
25 (suppl 1)
57-60
-
31
Campbell K R, Mahaffey K W, Lewis B E et al..
Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.
J Invasive Cardiol.
2000;
12(suppl F)
14F-19F
-
32
Bates E R.
Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes.
Curr Cardiol Rep.
2001;
3
348-354
-
33
Mahaffey K W.
Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
Curr Cardiol Rep.
2001;
3
362-370
-
34
Manfredi J A, Wall R P, Sane D C, Braden G A.
Lepirudin as a safe alternative for effective anticoagulation in patients with known heparin-induced thrombocytopenia undergoing percutaneous coronary intervention: case reports.
Catheter Cardiovasc Interv.
2001;
52
468-472
-
35
Lewis B E, Matthai Jr W H, Cohen M, Moses J W, Hursting M J, Leya F.
ARG-216/310/311 Study Investigators. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
Catheter Cardiovasc Interv.
2002;
57
177-184
-
36
Cochran K, DeMartini T J, Lewis B E et al..
Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia.
J Invasive Cardiol.
2003;
15
617-621
-
37
Mahaffey K W, Lewis B E, Wildermann N M et al..
ATBAT Investigators .
The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results.
J Invasive Cardiol.
2003;
15
611-616
-
38
Greinacher A, Lubenow N.
Recombinant hirudin in clinical practice: focus on lepirudin.
Circulation.
2001;
103
1479-1484
-
39
Greinacher A, Volpel H, Janssens U et al..
Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study.
Circulation.
1999;
99
73-80
-
40
Greinacher A, Janssens U, Berg G et al..
Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.
Circulation.
1999;
100
587-593
-
41
Eichler P, Friesen H J, Lubenow N, Jaeger B, Greinacher A.
Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance.
Blood.
2000;
96
2373-2378
-
42
Hafner G, Rupprecht H J, Luz M et al..
Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Eur Heart J.
1996;
17
1207-1215
-
43
Laubenthal F C, Grosch B, Szurawitzki G, Sabin G V.
Heparin-induced thrombocytopenia type II with early aortocoronary bypass occlusion and stent thrombosis after PTCA of the RCA-treatment with lepirudin (Refludan) and abciximab (Reopro) during recanalization of the RCA [in German].
Z Kardiol.
1999;
88
141-146
-
44
Pinto D S, Sperling R T, Tu T M, Cohen D J, Carrozza Jr J P.
Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
Catheter Cardiovasc Interv.
2003;
58
65-68
-
45
Serruys P W, Herrman J P, Simon R et al..
A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators.
N Engl J Med.
1995;
333
757-763
-
46
Hauptmann J.
Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs. A review of small-molecule thrombin inhibitors.
Eur J Clin Pharmacol.
2002;
57
751-758
-
47
Matsuo T, Koide M, Kario K.
Development of argatroban, a direct thrombin inhibitor, and its clinical application.
Semin Thromb Hemost.
1997;
23
517-522
-
48
Lewis B E, Wallis D E, Leya F, Hursting M J, Kelton J G.
Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.
Arch Intern Med.
2003;
163
1849-1856
-
49
Lewis B E, Wallis D E, Berkowitz S D et al..
ARG-911 Study Investigators. .
Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.
Circulation.
2001;
103
1838-1843
-
50
Reichert M G, MacGregor D A, Kincaid E H, Dolinski S Y.
Excessive argatroban anticoagulation for heparin-induced thrombocytopenia.
Ann Pharmacother.
2003;
37
652-654
-
51
Lewis B E, Matthai Jr W H, Cohen M, Moses J W, Hursting M J, Leya F.
ARG-216/310/311 Study Investigators .
Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.
Catheter Cardiovasc Interv.
2002;
57
177-184
-
52
Sciulli T M, Mauro V F.
Pharmacology and clinical use of bivalirudin.
Ann Pharmacother.
2002;
36
1028-1041
-
53
White H D, Aylward P E, Frey M J et al..
Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.
Circulation.
1997;
96
2155-2161
-
54
Bittl J A, Chaitman B R, Feit F, Kimball W, Topol E J.
Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study.
Am Heart J.
2001;
142
952-959
-
55
Lincoff A M, Bittl J A, Harrington R A et al..
REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
JAMA.
2003;
289
853-863
-
56
Lincoff A M, Kleiman N S, Kottke-Marchant K et al..
Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).
Am Heart J.
2002;
143
847-853
-
57
Pothoulakis A J, Neerukonda S K, Ansel G, Jantz R D.
Ancrod for coronary angioplasty.
Tex Heart Inst J.
1995;
22
342-346
-
58
Moore J A, Burket M W, Puri S, Temesy-Armos P, Lachant N, Skeel R.
Ancrod infusion for anticoagulation during and after PTCA in a patient with heparin-induced thrombocytopenia.
Cathet Cardiovasc Diagn.
1994;
32
286-287
-
59
Lathan L O, Staggers S L.
Ancrod: the use of snake venom in the treatment of patients with heparin-induced thrombocytopenia and thrombosis undergoing coronary artery bypass grafting: nursing management.
Heart Lung.
1996;
25
451-462
-
60
Prentice C R, Hampton K K, Grant P J, Nelson S R, Nieuwenhuizen W, Gaffney P J.
The fibrinolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products.
Br J Haematol.
1993;
83
276-281
-
61
Greinacher A, Amiral J, Dummel V, Vissac A, Kiefel V, Mueller-Eckhardt C.
Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay.
Transfusion.
1994;
34
381-385
-
62
Leroy J, Leclerc M H, Delahousse B et al..
Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216).
Semin Thromb Hemost.
1985;
11
326-329
-
63
Gouault-Heilmann M, Huet Y, Adnot S et al..
Low molecular weight heparin fractions as an alternative therapy in heparin-induced thrombocytopenia.
Haemostasis.
1987;
17
134-140
-
64
Greinacher A, Michels I, Mueller-Eckhardt C.
Heparin-associated thrombocytopenia: the antibody is not heparin specific.
Thromb Haemost.
1992;
67
545-549
-
65 Warkentin T E, Kelton J G. Interaction of heparin with platelets, including heparin-induced thrombocytopenia. In: Bounameaux H Low-Molecular-Weight Heparins in Prophylaxis and Therapy of Thromboembolic Diseases New York; Marcel Dekker 1994: 75-127
-
66
Chong B H, Ismail F, Cade J, Gallus A S, Gordon S, Chesterman C N.
Heparin-induced thrombocytopenia: studies with a new low-molecular-weight heparinoid, Org 10172.
Blood.
1989;
73
1592-1596
-
67
Magnani H N.
Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172).
Thromb Haemost.
1993;
70
554-561
-
68
Hale L P, Smith K, Braden G A, Owen J.
Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia.
Cathet Cardiovasc Diagn.
1998;
45
318-322
-
69
Cantor W J, Leblanc K, Garvey B, Watson K R, Rasymas A, Strauss B H.
Combined use of Orgaran and Reopro during coronary angioplasty in patients unable to receive heparin.
Catheter Cardiovasc Interv.
1999;
46
352-355
-
70
Reverter J C, Beguin S, Kessels H, Kumar R, Hemker H C, Coller B S.
Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis”.
J Clin Invest.
1996;
98
863-874
George D DangasM.D. Ph.D.
Cardiovascular Research Foundation
55 E. 59th Street, 6th Floor
New York, NY 10022
eMail: gdangas@crf.org
